133 related articles for article (PubMed ID: 16877188)
1. Successful palliation with octreotide of a neuroendocrine syndrome from malignant melanoma.
Jahng AW; Liao SS
J Pain Symptom Manage; 2006 Aug; 32(2):191-5. PubMed ID: 16877188
[TBL] [Abstract][Full Text] [Related]
2. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction.
Hisanaga T; Shinjo T; Morita T; Nakajima N; Ikenaga M; Tanimizu M; Kizawa Y; Maeno T; Shima Y; Hyodo I
Jpn J Clin Oncol; 2010 Aug; 40(8):739-45. PubMed ID: 20410056
[TBL] [Abstract][Full Text] [Related]
3. A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors.
Berković MC; Altabas V; Herman D; Hrabar D; Goldoni V; Vizner B; Zjacić-Rotkvić V
Coll Antropol; 2007 Jun; 31(2):531-4. PubMed ID: 17847934
[TBL] [Abstract][Full Text] [Related]
4. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors.
Chambers AJ; Pasieka JL; Dixon E; Rorstad O
Surgery; 2008 Oct; 144(4):645-51; discussion 651-3. PubMed ID: 18847650
[TBL] [Abstract][Full Text] [Related]
5. Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy.
Christante D; Pommier S; Givi B; Pommier R
Surgery; 2008 Dec; 144(6):885-93; discussion 893-4. PubMed ID: 19040993
[TBL] [Abstract][Full Text] [Related]
6. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms.
Pasieka JL; McEwan AJ; Rorstad O
Surgery; 2004 Dec; 136(6):1218-26. PubMed ID: 15657579
[TBL] [Abstract][Full Text] [Related]
7. Octreotide in the management of bowel obstruction in terminal ovarian cancer.
Mangili G; Franchi M; Mariani A; Zanaboni F; Rabaiotti E; Frigerio L; Bolis PF; Ferrari A
Gynecol Oncol; 1996 Jun; 61(3):345-8. PubMed ID: 8641613
[TBL] [Abstract][Full Text] [Related]
8. [A clinical study using octreotide in relieving gastrointestinal symptoms due to bowel obstruction in a terminally ill cancer patient].
Shima Y; Yamaguchi K; Miyata Y; Hyodo I; Yagi Y; Honke Y
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1377-82. PubMed ID: 15446560
[TBL] [Abstract][Full Text] [Related]
9. Metastatic neuroendocrine hepatic tumors: resection improves survival.
Musunuru S; Chen H; Rajpal S; Stephani N; McDermott JC; Holen K; Rikkers LF; Weber SM
Arch Surg; 2006 Oct; 141(10):1000-4; discussion 1005. PubMed ID: 17043278
[TBL] [Abstract][Full Text] [Related]
10. [Clinical efficacy of octreotide acetate in cancer patients with malignant bowel symptoms depend on terminal stage].
Uchino R; Kusano S; Hanada N; Ohara C; Okino T; Yamaguchi K
Gan To Kagaku Ryoho; 2011 Feb; 38(2):255-7. PubMed ID: 21368489
[TBL] [Abstract][Full Text] [Related]
11. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients.
Nikou GC; Toumpanakis C; Katsiari C; Charalambopoulos D; Sfikakis PP
J Clin Rheumatol; 2007 Jun; 13(3):119-23. PubMed ID: 17551375
[TBL] [Abstract][Full Text] [Related]
12. Comments on "Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients".
Schran HF; Hager DF
Pancreas; 2008 Oct; 37(3):334-5; author reply 336-7. PubMed ID: 18815560
[No Abstract] [Full Text] [Related]
13. Octreotide improved the quality of life in a child with malignant bowel obstruction caused by peritoneal dissemination of colon cancer.
Watanabe H; Inoue Y; Uchida K; Okugawa Y; Hiro J; Ojima E; Kobayashi M; Miki C; Kusunoki M
J Pediatr Surg; 2007 Jan; 42(1):259-60. PubMed ID: 17208578
[TBL] [Abstract][Full Text] [Related]
14. Octreotide treatment of carcinoid hypertensive crisis.
Warner RR; Mani S; Profeta J; Grunstein E
Mt Sinai J Med; 1994 Sep; 61(4):349-55. PubMed ID: 7969229
[TBL] [Abstract][Full Text] [Related]
15. [Interventional therapy of neuroendokrine tumors of the gastrointestinal tract].
Kettenbach J; Müller SL; Schindl M
Wien Klin Wochenschr; 2003; 115 Suppl 2():56-64. PubMed ID: 15518148
[TBL] [Abstract][Full Text] [Related]
16. Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency.
Woltering EA; Hilton RS; Zolfoghary CM; Thomson J; Zietz S; Go VL; Vinik AI; Vinik E; O'Dorisio TM; Mamikunian G
Pancreas; 2006 Oct; 33(3):250-4. PubMed ID: 17003646
[TBL] [Abstract][Full Text] [Related]
17. A pressing situation.
Scialla JJ; Hemnes AR
Am J Med; 2005 Dec; 118(12):1347-9. PubMed ID: 16378775
[No Abstract] [Full Text] [Related]
18. [Effective made of octreotide intravenous administration for malignant gastrointestinal obstruction in terminal cancer patients].
Tanimura K; Onda S; Mitsunobu M
Gan To Kagaku Ryoho; 2010 Oct; 37(10):1991-3. PubMed ID: 20948271
[TBL] [Abstract][Full Text] [Related]
19. [A case of successful treatment using octreotide acetate for occlusive ileus in terminal stage cancer].
Yoshioka S; Tsujie M; Ebisui C; Okubo K; Akitake H; Otsuka M; Maekawa T; Hama N; Kashiwazaki M; Taniguchi M; Konishi M; Fujimoto T
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2266-8. PubMed ID: 20037391
[TBL] [Abstract][Full Text] [Related]
20. Palliative radiation therapy of symptomatic recurrent bladder cancer.
Yi SK; Yoder M; Zaner K; Hirsch AE
Pain Physician; 2007 Mar; 10(2):285-90. PubMed ID: 17387350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
